New research indicates that individuals who come off new slimming jabs like Wegovy and Mounjaro can put back on shed pounds at a significantly accelerated pace than those who end traditional lifestyle regimens.
Published data in a leading medical journal demonstrates that while obese individuals can lose a large proportion of their total mass while undergoing treatment, the mass returns at an average rate of 0.8 kg per month once they quit.
"Individuals using such medications must be cognizant of the potential of quick rebound weight gain when the therapy ends," stated researcher Dr. Susan Jebb.
This pace of regain means a reversion to starting mass in about a year and a half.
Weighing Approaches
The analysis, which examined 37 of studies involving thousands of participants, contrasted the effects of these new drugs with older methods.
Scientists note that individuals who shed pounds through diet and exercise generally experience a more gradual creep back—perhaps 100 grams monthly—post-intervention.
Explaining the Fast Rebound
Doctors suggest the way of the drugs explains the heightened regain.
GLP-1 drugs copy a natural hormone called GLP-1, which moderates hunger.
"Sustained high doses of GLP-1 concentrations far above than normal might result in the body to produce less of its endogenous hormone, and could diminish sensitivity to its effects," explained Dr. Adam Collins, a nutrition researcher.
"Withdrawal of this hormone supplement results in hunger is unsuppressed, making excessive eating a significant risk."
An Ongoing Disease?
Medical guidelines suggest the injections for individuals with weight-linked medical conditions, alongside recommended diet and exercise modifications.
Many experts argue that, given the significant potential of relapse, the treatment should be considered life-long.
This view is reinforced by drug manufacturers, who note that the results "highlight the persistent character of obesity," comparing it to managing conditions like high blood pressure.
User Testimonies
People who have discontinued the medication explain a intense return of hunger.
"It was like a switch flipping and I was suddenly extremely hungry," said a patient.
The struggle is worsened if users have not developed lasting lifestyle or habit modifications during treatment.
Widespread Interest
Figures show that millions of adults in the UK have tried weight-loss jabs in the past year, with interest remaining high.
- Use is higher among women than males.
- The middle-aged age group shows the greatest usage rates.
- A large proportion access the drugs through private healthcare rather than the NHS.
In conclusion, researchers emphasize that while GLP-1 drugs are powerful agents for weight loss, they are not a standalone solution and maintained weight loss relies on ongoing lifestyle support.
